Megan Burger, PhD

Research Project:
Promoting Cooperative T cell Responses Against Lung Cancer

Grant Awarded:

Lung Cancer Discovery Award

Research Topics:

basic biologic mechanisms
biomarkers
combination therapies experimental therapeutics
immunology immunotherapy

Research Disease:

lung cancer

Lung cancer is the second most common cancer type and the leading cause of cancer-related deaths worldwide. Better treatments and biomarkers that predict patient response are greatly needed to reduce the impact of this terrible disease. Cancer immunotherapies that activate killer T cells of the immune system to seek out and eliminate cancer cells represent a promising new treatment approach for lung cancer. These therapies elicit curative responses in some patients and have been FDA-approved across multiple lung cancer types, including as a first-line therapy. Still, most patients do not benefit from this approach. We aim to understand why and identify ways to improve immunotherapy design to reach more patients. Our studies will use sophisticated mouse models of lung adenocarcinoma, the most common type of lung cancer, to understand what controls whether T cells can kill cancer cells and identify new immunotherapy approaches that improve T cell function.

Page last updated: October 3, 2023

Join the Patient & Caregiver Network

End Youth Vaping

10 Tips to Protect Yourself from Unhealthy Air

State of the Air Key Findings

Become an Advocate

Events Near You

Megan Burger, PhD

A Breath of Fresh Air in Your Inbox

Thank You!

Make a Donation

Become a Lung Health Insider

Select Your Location

Change Language

Lung HelpLine

1-800-LUNG-USA